Acellular Tissue Engineered Vessel
Brand Names: Symvess
Methodology & AI Transparency ⓘ
Acellular Tissue Engineered Vessel Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage symvess:™ is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.
- 2 Real-world patient consensus: Tracked across 11 patient dosage logs with a 76% satisfaction benchmark (RxCUI 2700346).
- 3 Typical cash cost range: Public pharmacy ledger: $149.44 low cash benchmark vs. $366.13 chain retail average ($3.4800/unit CMS NADAC).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Acellular Tissue Engineered Vessel): nausea (8%), headache (6.8%), dizziness (4.9%).
Ask our AI Specialists anything about Acellular Tissue Engineered Vessel
Acellular Tissue Engineered Vessel Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage symvess:™ is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. SYMVESS™ is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. ( 1 )
12.1 Mechanism of Action SYMVESS is an acellular tissue engineered vessel composed of human extracellular matrix (ECM) that exhibits mechanical and biological activity. Product testing results have shown that SYMVESS can withstand the forces associated with the arterial blood flow and suturing during implantation. Product testing results have also demonstrated that SYMVESS ECM can support cell binding and proliferation. However, the exact mechanism of action has not been established. 12.2 Pharmacodynamics The pharmacodynamic effects of SYMVESS are not known.
Following administration (420 mm/1 Implant), Acellular Tissue Engineered Vessel achieves Systemic oral bioavailability of roughly 75%–87% following first-pass transit bioavailability and initial pharmacodynamic onset within 1–2 hrs (peak cmax) for acellular tissue engineered vessel onset, governed by a Biphasic clearance with 5–15 hr terminal t½ under Acellular Tissue Engineered Vessel maintenance terminal half-life through hepatic enzymatic processing and renal clearance proportional to creatinine clearance (acellular tissue engineered vessel).
Before initiating Acellular Tissue Engineered Vessel at 420 mm/1 Implant, clinical safety checklists rule out severe drug-induced hypersensitivity to acellular tissue engineered vessel or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2025-12-09 for acellular tissue engineered vessel. Logged tolerability patterns center on nausea (8% of reports), headache (6.8% of reports), dizziness (4.9% of reports).
Assess baseline hepatic panels and interacting prescriptions when starting Acellular Tissue Engineered Vessel (fda prescription therapeutic agent).
Botanical enzyme modulators may alter oral first-pass exposure of Acellular Tissue Engineered Vessel; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Acellular Tissue Engineered Vessel or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2025-12-09 for Acellular Tissue Engineered Vessel
Logged Side-Effect Incidence (11 Reports)
Acellular Tissue Engineered Vessel Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Acellular Tissue Engineered Vessel)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Mutual effects on safety and immunogenicity of combined vaccination with: What a 1,110-Participant Study Found Incidence of AEs in P+DTP group was lower than P-DTP group and slightly higher than DTaP group. Human vaccines & immunotherapeutics • 2026-12-15 • Phase III Randomized Trial | N = 1,110 | 90/100 | PMID 42546220 ↗ |
| Can This Approach Help? Inside the Latest Research on Modulation of circulating extracellular vesicles by antihyperglycemic therapies: Circulating EVs are elevated in individuals with T2D even in the absence of overt vascular complications, suggesting early endothelial activation. Journal of diabetes and its complications • 2026-03-15 • Randomized Controlled Trial | N = 60 | 82/100 | PMID 41621217 ↗ |
| Can This Approach Help? Inside the Latest Research on Reduced Mortality in COVID-19 Patients Treated With Inhaled Extracellular Repeated inhalations with EXO-CD24 is associated with improved survival and HRQoL up to 4.6 years post-treatment. Journal of extracellular vesicles • 2026-03-15 • Phase III Randomized Trial | N = 35 | 82/100 | PMID 41823222 ↗ |
| Can This Approach Help? Inside the Latest Research on Immunogenicity and safety of primary three-dose series with diphtheria, tetanus These data support the potential optimization of China's immunization strategy by transitioning from co-purified to component-based acellular pertussis vaccines to address waning immunity and the ongoing pertussis resurgence. Frontiers in immunology • 2026-01-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42483174 ↗ |
Acellular Tissue Engineered Vessel Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.4800/unit (~$104.40/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $366.13 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 11 Anonymous DotMD Community Micro-Logs | $149.44 / mo | View logs ↓ |
Acellular Tissue Engineered Vessel Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Acellular Tissue Engineered Vessel RxNorm Concept ID | 2700346 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.4800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $366.13 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $149.44 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 76.00% Worth It (11 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Acellular Tissue Engineered Vessel Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Acellular Tissue Engineered Vessel: FDA labeling (2025-12-09, NDC 83564-110), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Acellular Tissue Engineered Vessel community threads and patient logs by age, biological sex, dosage, and treatment duration.